The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.
 
Dickon Hayne
Consulting or Advisory Role - BMS; Pacific Edge Biotechnology; Urogen pharma
Research Funding - AstraZeneca (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Abbott/AbbVie
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Andrew James Martin
No Relationships to Disclose
 
Steve P McCombie
No Relationships to Disclose
 
Danka Sinikovic Zebic
Speakers' Bureau - Merck
 
Patricia A. Bastick
No Relationships to Disclose
 
Emma Kate Beardsley
No Relationships to Disclose
 
Mark Frydenberg
Leadership - Genesis Cancer Care
Stock and Other Ownership Interests - Telix Pharmaceuticals (I)
 
William Green
No Relationships to Disclose
 
Jeremy Grummet
Stock and Other Ownership Interests - MRI Pro
Honoraria - Biobots; BK Ultrasound; Mundipharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Cynthia Hawks
No Relationships to Disclose
 
Joseph Ischia
Stock and Other Ownership Interests - Jiffystent Pty Ltd
Honoraria - Bayer
Speakers' Bureau - Bayer
Patents, Royalties, Other Intellectual Property - "Methods and Compositions for Inhibiting a Noxious Insult using Zinc and salts thereof"
Travel, Accommodations, Expenses - Bayer
 
Andrew Mitterdorfer
No Relationships to Disclose
 
Manish Patel
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen
 
Matthew Roberts
Consulting or Advisory Role - BXTAccelyon
Research Funding - Mundipharma (Inst)
 
Shomik Sengupta
Other Relationship - Board director (pro-bono), Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
 
Ratnesh Kumar Srivastav
No Relationships to Disclose
 
Andrew David Redfern
Honoraria - AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.